Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI). PROTACs are potentially superior to conventional small molecule inhibitors (SMIs) because of their unique mechanism of action (MOA...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Hematol Oncol
Glavni autori: He, Yonghan, Khan, Sajid, Huo, Zhiguang, Lv, Dongwen, Zhang, Xuan, Liu, Xingui, Yuan, Yaxia, Hromas, Robert, Xu, Mingjiang, Zheng, Guangrong, Zhou, Daohong
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7384229/
https://ncbi.nlm.nih.gov/pubmed/32718354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00924-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items